Pharmacogenomic considerations in the opioid management of pain

Genome Medicine

Volumn 2, Issue 9, 2010, Pages

  Jannetto, Paul J ^a   Bratanow, Nancy C ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Midwest Comprehensive Pain Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADRENALIN; CODEINE; DOPAMINE; FENTANYL; GLYCOPROTEIN P; METHADONE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NORADRENALIN; OPIATE; OXYCODONE; TRAMADOL;

ABSENTEEISM; ADVERSE DRUG REACTION; CANCER PAIN; CLINICAL FEATURE; CONSTIPATION; DRUG EFFICACY; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; NAUSEA; PAIN; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; VOMITING;

EID: 78751683129     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm187     Document Type: Review

References (22)

1. World Health Organization Cancer Pain Relief and Palliative Care 1990, Technical Report Series No 804. Geneva: WHO, World Health Organization.
2. Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001, 84:587-593. 10.1054/bjoc.2001.1680, 2363790, 11237376.
3. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001, 19:2542-2554.
4. Chronic Pain in America: Roadblocks to Relief. , http://www.ampainsoc.org/links/roadblocks/
5. Skorpen F, Laugsand EA, Klepstad P, Kaasa S. Variable response to opioid treatment: any genetic predictors within sight?. Palliat Med 2008, 22:310-327. 10.1177/0269216308089302, 18541635.
6. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008, 83:559-566. 10.1038/sj.clpt.6100385, 17898703.
7. Galley HF, Mahdy A, Lowes DA. Pharmacogenetics and anesthesiologists. Pharmacogenomics 2005, 6:849-856. 10.2217/14622416.6.8.849, 16296947.
8. Ingelman-Sunberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004, 25:193-200. 10.1016/j.tips.2004.02.007, 15063083.
9. Fagerlund TH, Braaten O. No pain relief from codeine? An introduction to pharmacogenetics. Acta Anaesthesiol Scand 2001, 45:140-149. 10.1034/j.1399-6576.2001.450203.x, 11167158.
10. Stamer UM, Kehnen K, Hothker F, Wolf S, Hoeft A. Impact of CYP2D6 on postoperative tramadol analgesia. Pain 2003, 105:231-238. 10.1016/S0304-3959(03)00212-4, 14499440.
11. Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 2005, 25:521-544. 10.1002/med.20035, 15952175.
12. Darbari DS, VanSchaik RHN, Capparelli EV, Rana S, McCarter R, VandenAnker J. UGT2B7 promoter variant -840G > A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008, 83:200-202. 10.1002/ajh.21051, 17724700.
13. Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 2009, 10.1007/s00280-009-1029-2, 19466410.
14. Niemi G, Greivik H. The minimally effective concentration of adrenaline in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl, and adrenaline after surgery-a randomized, double-blind, dose-finding study. Acta Anaesthesiol Scand 2003, 47:439-450. 10.1034/j.1399-6576.2003.00077.x, 12694144.
15. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane bound catechol O-demethyltransferase: a revised mechanism and description of the thermoliable variant of the enzyme. Biochemistry 1995, 34:4202-4210. 10.1021/bi00013a008, 7703232.
16. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. The Val58Met polymorphism of the human catechol O-demethyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005, 116:73-78. 10.1016/j.pain.2005.03.032, 15927391.
17. Rakvåg TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008, 4:64-76. 2644687, 19094200.
18. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118A > G polymorphism n the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004, 48:1232-1239. 10.1111/j.1399-6576.2004.00517.x, 15504181.
19. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006, 50:787-792. 10.1111/j.1399-6576.2006.01058.x, 16879459.
20. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006, 105:334-337. 10.1097/00000542-200608000-00016, 16871067.
21. Kadiev E, Patel V, Rad P, Thankachan L, Tram A, Weinlein M, Woodfin K, Raffa RB, Nagar S. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol 2008, 4:77-91. 10.1517/17425255.4.1.77, 18370860.
22. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010, 26 Suppl 10:S16-S20. 10.1097/AJP.0b013e3181c49e11, 20026961.